Postmenopausal hormone therapy and ductal carcinoma in situ: A population-based case-control study

Cancer Epidemiology

Volumn 36, Issue 2, 2012, Pages 161-168

  Calvocoressi, Lisa ^a   Stowe, Meredith H ^a   Carter, Darryl ^a   Claus, Elizabeth B ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carcinoma; Case control studies; Hormone therapy; Intraductal; Noninfiltrating; Postmenopause

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MONOTHERAPY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO;

EID: 84858795547     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.01.001     Document Type: Article

References (42)

1. Allegra C., Aberle D., Ganschow P., Hahn S., Lee C., Millon-Underwood S., et al. National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ September 22-24. J Natl Cancer Inst 2009, 102(3):161-169.
2. SEER Cancer Statistics Review 1975-2007, National Cancer Institute, Bethesda, MD. S.F.K.C. Altekruse, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl (Eds.).
3. Warnberg F., Yuen J., Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 2000, 355(9205):724-725.
4. Trentham-Dietz A., Newcomb P.A., Storer B.E., Remington P.L. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2000, 9(7):697-703.
5. Wohlfahrt J., Rank F., Kroman N., Melbye M. A comparison of reproductive risk factors for CIS lesions and invasive breast cancer. Int J Cancer 2004, 108(5):750-753.
6. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010, 41:139-141.
7. Claus E.B., Stowe M., Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001, 93(23):1811-1817.
8. Kabat G.C., Kim M.Y., Woods N.F., Habel L.A., Messina C.R., Wactawski-Wende J., et al. Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control 2011, [Epub ahead of print].
9. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350(9084):1047-1059.
10. Collins J., Blake J., Crosignani P. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005, 11(6):545-560.
11. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009, 113(1):65-73.
12. Leonard G., Swain S. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004, 96(12):906-920.
13. Virnig B., Tuttle T., Shamliyan T., Kane R. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010, 102(3):170-178.
14. Daling J., Malone K., Doody D., Voigt L., Bernstein L., Coates R., et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002, 95(12):2455-2464.
15. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92(4):328-332.
16. Gadducci A., Cosio S., Genazzani A. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol 2007, 23(11):625-631.
17. Minisini A., Menis J., Valent F., Andreetta C., Alessi B., Pascoletti G., et al. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anticancer Drugs 2009, 20(6):503-507.
18. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332(24):1589-1593.
19. Li C., Malone K., Daling J. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). CCC - Cancer Causes Control 2006, 17(5):695-703.
20. Sandini L., Pentti K., Tuppurainen M., Krger H., Honkanen R. Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 2008, 15(2):282-289.
21. Shantakumar S., Terry M., Paykin A., Teitelbaum S., Britton J., Moorman P., et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007, 165(10):1187-1198.
22. Pike M.C., Ross R.K., Spicer D.V. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998, 147(8):718-721.
23. Malmgren J.A., Atwood M.K., Kaplan H.G. Increase in mammography detected breast cancer over time at a community based regional cancer center: a longitudinal cohort study 1990-2005. BMC Cancer 2008, 8:131.
24. Brinton L.A., Hoover R., Fraumeni J.F. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986, 54(5):825-832.
25. Chlebowski R., Hendrix S., Langer R., Stefanick M., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289(24):3243-3253.
26. Gapstur S.M., Morrow M., Sellers T.A. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999, 281(22):2091-2097.
27. Henrich J.B., Kornguth P.J., Viscoli C.M., Horwitz R.I. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998, 51(12):1277-1283.
28. Kerlikowske K., Miglioretti D., Ballard-Barbash R., Weaver D., Buist D.S.M., Barlow W., et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 2003, 21(23):4314-4321.
29. Longnecker M.P., Bernstein L., Paganini-Hill A., Enger S.M., Ross R.K. Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 1996, 5(12):961-965.
30. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006, 108(6):1354-1360.
31. Reeves G., Beral V., Green J., Gathani T., Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006, 7(11):910-918.
32. Reinier K., Vacek P., Geller B. Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat 2007, 103(3):343-348.
33. Schairer C., Byrne C., Keyl P.M., Brinton L.A., Sturgeon S.R., Hoover R.N. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994, 5(6):491-500.
34. Stanford J.L., Weiss N.S., Voigt L.F., Daling J.R., Habel L.A., Rossing M.A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995, 274(2):137-142.
35. Phillips L., Millikan R., Schroeder J., Barnholtz Sloan J., Levine B. Reproductive and hormonal risk factors for ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2009, 18(5):1507-1514.
36. Flesch Janys D., Slanger T., Mutschelknauss E., Kropp S., Obi N., Vettorazzi E., et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008, 123(4):933-941.
37. Tsai S., Stefanick M., Stafford R. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 2010, 18(4). [Epub ahead of print].
38. Biglia N., Sgro L., Defabiani E., De Rosa G., Ponzone R., Marenco D., et al. The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 2005, 31(5):467-472.
39. Phipps A., Li C., Kerlikowske K., Barlow W., Buist D.S.M. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev 2010, 19(6):1643-1654.
40. Millikan R., Dressler L., Geradts J., Graham M. The need for epidemiologic studies of in situ carcinoma of the breast. Breast Cancer Res Treat 1995, 35(1):65-77.
41. Lari S.A., Kuerer H.M. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011, 2:232-261.
42. Chen W., Hankinson S., Schnitt S., Rosner B., Holmes M., Colditz G. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004, 101(7):1490-1500.